DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2pkjlm/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Heptares Therapeutics Ltd.
- Lightlake Therapeutics Inc.
- Omeros Corporation
- Polleo Pharma Limited
- Teva Pharmaceutical Industries Limited
Drug Profiles
- armodafinil
- naloxone hydrochloride
- OMS-527
- Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders
- Small Molecules for Binge Eating Disorder
For more information visit http://www.researchandmarkets.com/research/2pkjlm/binge_eating
